Endometrioid carcinomas of the endometrium - DOGHRI, Raoudha
29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
15 °P sammeln
  • Broschiertes Buch

Endometrial cancer is the fourth most common cancer in women after breast, colon and lung cancer. Although prognostic factors for endometrial cancers are well established, the identification of new biomarkers could improve the understanding of the molecular pathways of the disease and open the horizon for new theranostic factors. The mutational status of TP53 protein is one of the most important molecular factors predicting the prognosis in endometrial carcinoma. In this same framework we performed an analysis of the immunohistochemical expression of p53 in endometrial carcinomas of grade 2…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Endometrial cancer is the fourth most common cancer in women after breast, colon and lung cancer. Although prognostic factors for endometrial cancers are well established, the identification of new biomarkers could improve the understanding of the molecular pathways of the disease and open the horizon for new theranostic factors. The mutational status of TP53 protein is one of the most important molecular factors predicting the prognosis in endometrial carcinoma. In this same framework we performed an analysis of the immunohistochemical expression of p53 in endometrial carcinomas of grade 2 and to study its association with different anatomical-clinical features. In our study, 17% of patients overexpressed p53 (mutated profile). Overexpression of p53 was correlated with advanced FIGO stage (p= 0.027). Relapse-free survival was significantly better for the wild-type p53 group than for the mutated p53 group (p:0.02). Our results suggest that p53 may be a poor prognostic marker for grade 2 endometrioid carcinomas.
Autorenporträt
DOGHRI Raoudha é Professor Associado da Faculdade de Medicina de Tunis (Anatomia Patológica). Possui Mestrado em Genética Patológica (2016), Diploma em Metodologia de Pesquisa (2017) e Mestrado em Oncogenética (2022).